⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16272959 | 1.00 | — | — | |
| SCHEMBL12657110 | 1.00 | — | — | |
| SCHEMBL20793850 | 0.86 | PIK3CD (0.31) | — | |
| SCHEMBL18946495 | 0.86 | PIK3CD (0.31) | — | |
| SCHEMBL7289429 | 0.86 | PIK3CD (0.31) | — | |
| SCHEMBL12363905 | 0.85 | PIK3CD (0.31) | — | |
| SCHEMBL102262 | 0.85 | PIK3CD (0.45) | — | |
| SCHEMBL10734045 | 0.82 | — | — | |
| SCHEMBL19820177 | 0.82 | — | — | |
| SCHEMBL14748102 | 0.80 | PIK3CD (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240216377-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2024-07-04 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11834433-B2 | Compounds | INFLAZOME LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040229818-A1 | Hepatitis C inhibitor compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
| US-20040229818-A1 | Hepatitis C inhibitor compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
| US-20040224900-A1 | Hepatitis C inhibitor peptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |